AnaptysBio (MEX:ANAB) Other Current Liabilities: MXN100 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ANAB AnaptysBio Inc MEX:ANAB
66 GF Score
Price MXN445.25
GF Value MXN478.35
! 2 Warning Signs
View Full Analysis

What is AnaptysBio Other Current Liabilities?

AnaptysBio MEX:ANAB 66 Other Current Liabilities is MXN100 Mil as of Mar. 2026. GuruFocus rates MEX:ANAB with a GF Score™ of 66/100 and a GF Value™ of MXN478.35. The stock has 2 warning signs investors should review.

AnaptysBio's other current liabilities for the quarter that ended in Mar. 2026 was MXN100 Mil.

AnaptysBio's quarterly other current liabilities increased from Sep. 2025 (MXN165 Mil) to Dec. 2025 (MXN200 Mil) but then declined from Dec. 2025 (MXN200 Mil) to Mar. 2026 (MXN100 Mil).

AnaptysBio's annual other current liabilities increased from Dec. 2023 (MXN122 Mil) to Dec. 2024 (MXN176 Mil) and increased from Dec. 2024 (MXN176 Mil) to Dec. 2025 (MXN200 Mil).

AnaptysBio Other Current Liabilities Related Terms

AnaptysBio Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for AnaptysBio's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AnaptysBio Other Current Liabilities Chart

AnaptysBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.69 104.87 122.23 176.21 199.76

AnaptysBio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.73 120.51 165.23 199.76 99.79
MEX:ANAB
66GF Score
AnaptysBio Inc MEX:ANAB
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AnaptysBio Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN100 Mil mean?
AnaptysBio (MEX:ANAB) has a Other Current Liabilities of MXN100 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AnaptysBio.
Is AnaptysBio's Other Current Liabilities too high?
AnaptysBio's current Other Current Liabilities is MXN100 Mil. Overall, AnaptysBio has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's Other Current Liabilities compare to ABSI and TSHA?
AnaptysBio's Other Current Liabilities of MXN100 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on AnaptysBio. AnaptysBio's current Other Current Liabilities is MXN100 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
AnaptysBio (MEX:ANAB) has a current Other Current Liabilities of MXN100 Mil. The stock's GF Value™ is MXN478.35, compared to a current price of MXN445.25 — trading 6.9% below its estimated fair value. The current Other Current Liabilities is MXN100 Mil. AnaptysBio's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For AnaptysBio (MEX:ANAB), the current Other Current Liabilities is MXN100 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AnaptysBio (MEX:ANAB) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be undervalued. The current stock price of MXN445.25 is trading 6.9% below its estimated GF Value™ of MXN478.35.

Key valuation signals for MEX:ANAB:

  • Other Current Liabilities: MXN100 Mil
  • GF Value™: MXN478.35 vs. price of MXN445.25 (6.9% below fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the MEX:ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges ANAB:USA0HFQ:UKAN6:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
66GF Score

Get the complete analysis for MEX:ANAB

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN445.25
Price
MXN478.35
GF Value